Tff Pharmaceuticals Inc (TFFP)

$5.9017

Market is closed - opens 8 PM, 26 Feb 2024

Insights on Tff Pharmaceuticals Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 74.4% return, outperforming this stock by 145.4%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 242.0% return, outperforming this stock by 340.4%

Performance

  • $5.71
    $6.00
    $5.90
    downward going graph

    3.22%

    Downside

    Day's Volatility :4.83%

    Upside

    1.67%

    downward going graph
  • $4.55
    $23.00
    $5.90
    downward going graph

    22.88%

    Downside

    52 Weeks Volatility :80.22%

    Upside

    74.35%

    downward going graph

Returns

PeriodTff Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
-20.0%
12.8%
0.0%
6 Months
-39.62%
11.6%
0.0%
1 Year
-70.97%
15.1%
-6.4%
3 Years
-98.45%
28.9%
-22.6%

Highlights

Market Capitalization
14.0M
Book Value
$5.79
Earnings Per Share (EPS)
-12.75
Wall Street Target Price
40.5
Profit Margin
0.0%
Operating Margin TTM
-1883.01%
Return On Assets TTM
-85.11%
Return On Equity TTM
-150.44%
Revenue TTM
932.3K
Revenue Per Share TTM
0.57
Quarterly Revenue Growth YOY
168.0%
Gross Profit TTM
-21.2M
EBITDA
-23.4M
Diluted Eps TTM
-12.75
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-12.0
EPS Estimate Next Year
-3.64
EPS Estimate Current Quarter
-0.11
EPS Estimate Next Quarter
-0.09

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Tff Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 586.24%

Current $5.90
Target $40.50

Technicals Summary

Sell

Neutral

Buy

Tff Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Tff Pharmaceuticals Inc
Tff Pharmaceuticals Inc
11.35%
-39.62%
-70.97%
-98.45%
-95.34%
Moderna, Inc.
Moderna, Inc.
-4.6%
-14.37%
-30.73%
-33.38%
345.54%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.48%
18.04%
29.62%
113.96%
133.41%
Novo Nordisk A/s
Novo Nordisk A/s
17.34%
33.21%
74.36%
242.01%
399.49%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.6%
24.03%
49.67%
98.17%
130.83%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Tff Pharmaceuticals Inc
Tff Pharmaceuticals Inc
NA
NA
NA
-12.0
-1.5
-0.85
NA
5.79
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-12.46
-0.22
-0.07
NA
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
27.77
27.77
1.97
44.85
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
45.7
45.7
4.49
3.31
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.77
30.77
0.58
16.74
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Tff Pharmaceuticals Inc
Tff Pharmaceuticals Inc
Buy
$14.0M
-95.34%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$37.9B
345.54%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$105.9B
133.41%
27.77
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$550.7B
399.49%
45.7
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$110.2B
130.83%
30.77
36.68%

Institutional Holdings

  • Carlson Capital LP

    8.24%
  • AIGH Capital Management, LLC

    4.49%
  • DRW Securities, LLC

    1.69%
  • Vanguard Group Inc

    1.43%
  • Worth Venture Partners, LLC

    1.09%
  • Geode Capital Management, LLC

    0.43%

Corporate Announcements

  • Tff Pharmaceuticals Inc Earnings

    Tff Pharmaceuticals Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

tff pharmaceuticals, inc. is a clinical-stage biopharma company focused on developing and commercializing drug products based on its patented thin film freezing (tff) technology. our patented thin film freezing (tff) platform makes it possible to turn more molecules into inhalable therapies. this novel technology provides high absorption and yield, uniform particle size, gentle process and endless possibilities. tff pharmaceuticals has two lead drug candidates: voriconazole inhalation powder and tac-lac inhalation powder. the company plans to add to this pipeline by collaborating with large pharmaceutical partners. the tff platform is protected by 42 patents issued or pending in the us and internationally.

Organization
Tff Pharmaceuticals Inc
Employees
15
CEO
Dr. Harlan F. Weisman
Industry
Health Technology

FAQs